GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » Selling, General, & Admin. Expense

Lucid Diagnostics (Lucid Diagnostics) Selling, General, & Admin. Expense : $32.90 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Lucid Diagnostics's selling, general, & admin. expense for the three months ended in Mar. 2024 was $8.26 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $32.90 Mil.


Lucid Diagnostics Selling, General, & Admin. Expense Historical Data

The historical data trend for Lucid Diagnostics's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucid Diagnostics Selling, General, & Admin. Expense Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
0.96 2.84 18.04 40.11 35.66

Lucid Diagnostics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.03 7.86 8.16 8.61 8.26

Competitive Comparison of Lucid Diagnostics's Selling, General, & Admin. Expense

For the Medical Devices subindustry, Lucid Diagnostics's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucid Diagnostics's Selling, General, & Admin. Expense Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's Selling, General, & Admin. Expense falls into.



Lucid Diagnostics Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lucid Diagnostics  (NAS:LUCD) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Lucid Diagnostics Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucid Diagnostics (Lucid Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Executives
Stanley Lapidus director 101 HARTWELL AVE., LEXINGTON MA 02421
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc. 10 percent owner 360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog director, officer: Chief Executive Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath officer: Chief Financial Officer C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw director 150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov director
David F Wurtman officer: Chief Medical Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165